You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 36 No. 10, October 1979 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

The Variable Natural History of Subacute Sclerosing Panencephalitis

A Study of 118 Cases From the Middle East

Winthrop S. Risk, PhD, MD; Fuad Sami Haddad, MD

Arch Neurol. 1979;36(10):610-614.


Abstract

• A variable natural history was found in a standardized follow-up study of 118 patients with subacute sclerosing panencephalitis (SSPE). Only 20% followed the sequence: behavior change, mental deterioration, periodic attacks, severe debility, and death within a year. Six stages were identified: O, subtle psychointellectual symptoms; 1, obvious psychointellectual and neurological changes; 2, stereotyped attacks; 3, vegetative psychomotor condition; 4, improvement; 5, relapse. Illness began in stage 0 for 32%; 1, 36%; 2,19%; 1 and 2 simultaneously, 13%. In early development, 77% were hyperactive, and 27% had psychointellectual difficulties one to five years prior to obvious illness. The average duration of each stage was as follows: stage O, two years; 1, 2.5 months; 2, 7.5 months; 3, 5.5 months; 4, 3.5 years; 5, 1.5 years. Noteworthy improvements and plateaus occurred in more than half of the patients. In stage 4, improvement was long-term and substantial for 5% and modest for 18%. Survival followed an exponential curve with an average half-life of 1.8 years; 41% of the patients survived beyond two years. Half of the patients passed through neither stage 0 nor stage 4; their half-life was 0.7 years. The remainder had a half-life of 3.0 years.



Author Affiliations

From the School of Medicine (Dr Risk) and the Section of Neurological Surgery (Dr Haddad), American University Medical Center, Beirut, Lebanon. Dr Risk is now with the University of Iowa Hospitals and Clinics, Iowa City. Presented in part at the First International Congress of Child Neurology, Toronto, Oct 6, 1975.


Footnotes

Accepted for publication Jan 29, 1979.

Reprint requests to Department of Neurology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242 (Dr Risk).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Nonconvulsive Status Epilepticus on Electroencephalography in a Case With Subacute Sclerosing Panencephalitis
Aydin et al.
J Child Neurol 2006;21:256-260.
ABSTRACT  

Improvement of SSPE by intrathecal infusion of {alpha}-IFN
Kurata et al.
Neurology 2004;63:398-399.
FULL TEXT  

Fulminating Adult-Onset Subacute Sclerosing Panencephalitis in a 49-Year-Old Man
Gagnon and Bouchard
Arch Neurol 2003;60:1160-1161.
ABSTRACT | FULL TEXT  

Combined Treatment With Subcutaneous Interferon-{alpha}, Oral Isoprinosine, and Lamivudine for Subacute Sclerosing Panencephalitis
Aydin et al.
J Child Neurol 2003;18:104-108.
ABSTRACT  

Subacute Sclerosing Panencephalitis: Clinical and Magnetic Resonance Imaging Evaluation of 36 Patients
Ozturk et al.
J Child Neurol 2002;17:25-29.
ABSTRACT  

Interleukin-1{beta}, Interleukin-1 Receptor Antagonist Levels in Patients With Subacute Sclerosing Panencephalitis and the Effects of Different Treatment Protocols
Haspolat et al.
J Child Neurol 2001;16:417-420.
ABSTRACT  

Lymphocyte Subsets and Inflammatory Mediators in Patients With Subacute Sclerosing Panencephalitis
Tekgul et al.
J Child Neurol 1999;14:418-421.
ABSTRACT  

{beta}-Interferon Plus Inosiplex in the Treatment of Subacute Sclerosing Panencephalitis
Anlar et al.
J Child Neurol 1998;13:557-559.
ABSTRACT  

Alpha-Interferon in the Treatment of Subacute Sclerosing Panencephalitis
Fayad et al.
J Child Neurol 1997;12:486-488.
ABSTRACT  

Mental Assessment in Subacute Sclerosing Panencephalitis: Hacettepe Cognitive Short Assessment Scale
Oktem et al.
J Child Neurol 1997;12:398-403.
 

Use of a Brief Assessment Examination in a Study of Subacute Sclerosing Panencephalitis
Nester
J Child Neurol 1996;11:173-180.
ABSTRACT  

Fulminant Subacute Sclerosing Panencephalitis in Association With Pregnancy
Wirguin et al.
Arch Neurol 1988;45:1324-1325.
ABSTRACT  

Myoclonus in a Case of Suspected Progressive Rubella Panencephalitis
Abe et al.
Arch Neurol 1983;40:98-100.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1979 American Medical Association. All Rights Reserved.